Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400652 | 1.00 | ATR (0.45) | ATRL3MBTL1GSK3BDYRK1AMKNK2 | |
| SCHEMBL4664375 | 0.84 | NPC1 (0.53) | MAP4K4CDK1EGFRSRCNPC1 | |
| SCHEMBL12705673 | 0.84 | GAA (0.43) | ATRL3MBTL1MAP4K4FGFR4AAK1 | |
| SCHEMBL17265777 | 0.84 | EGFR (0.42) | ATRGSK3BDYRK1AMKNK2MAP4K4 | |
| SCHEMBL690643 | 0.84 | CDK1 (0.49) | MAP4K4FGFR4CDK1EGFRSRC | |
| SCHEMBL18814953 | 0.84 | L3MBTL1 (0.49) | ATRL3MBTL1GSK3BDYRK1AMKNK2 | |
| SCHEMBL19890987 | 0.84 | L3MBTL1 (0.44) | ATRL3MBTL1GSK3BDYRK1AMKNK2 | |
| SCHEMBL18805592 | 0.84 | L3MBTL1 (0.68) | ATRL3MBTL1GSK3BDYRK1AMKNK2 | |
| SCHEMBL10288086 | 0.83 | GSK3B (0.54) | ATRGSK3BDYRK1AMAP4K4PTGER1 | |
| SCHEMBL691488 | 0.83 | CDK1 (0.48) | MAP4K4FGFR4CDK1EGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024159094-A1 | PYRIMIDINYL (HETERO)AROMATIC AMINOPYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES | ENLIVEN INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-09 | — | — | US | disclosed |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-09 | — | — | US | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| WO-2023108108-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-114853756-B | Preparation process of compound Tomivosertib | 武汉九州钰民医药科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-114853756-A | Preparation process of compound Tomivosertib | 武汉九州钰民医药科技有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-2985283-B1 | ANTI-ANGIOGENESIS COMPOUND, INTERMEDIATE AND USE THEREOF | GUANGZHOU KANGRUI BIOLOGICAL PHARMACEUTICAL TECH CO LTD (CN) | 2021-10-06 | — | — | EP | disclosed |
| US-10793551-B2 | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 | Effector Therapeutics Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| EP-3521289-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| CN-106795162-B | Mnk inhibitors and methods related thereto | 效应治疗股份有限公司 | 2019-07-16 | — | — | CN | disclosed |
| US-20190152988-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-05-23 | — | — | US | disclosed |
| WO-2019079369-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190119256-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-04-25 | — | — | US | disclosed |
| CN-108602805-A | Isoindoline, azaisoindoline, indenone and the dihydro azepine indone inhibitor of MNK1 and MNK2 | 效应治疗股份有限公司 | 2018-09-28 | — | — | CN | disclosed |
| CN-106795162-A | Mnk inhibitors and methods related thereto | 效应治疗股份有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| WO-2017075394-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119256-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | NEK5, MINK1, NIM1K | ATR 2096/4885L3MBTL1 2757/4885GSK3B 306/4885 |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | ATR 552/4885L3MBTL1 1038/4885GSK3B 451/4885 |
| US-20190152988-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | NEK9, NEK2, NEK3 | ATR 2455/4885L3MBTL1 4161/4885GSK3B 423/4885 |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | ATR 552/4885L3MBTL1 1038/4885GSK3B 451/4885 |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | NEK9, NEK2, NEK3 | ATR 2455/4885L3MBTL1 4161/4885GSK3B 423/4885 |
| US-10793551-B2 | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 | NEK5, MINK1, NIM1K | ATR 2096/4885L3MBTL1 2757/4885GSK3B 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.